Skip to main content

XFOR

Stock
Health Care
Biotechnology

Performance overview

XFOR Price
Price Chart

Forward-looking statistics

Beta
1.43
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Company info

SectorHealth Care
IndustryBiotechnology
Employees88
Market cap$169.6M

Fundamentals

Enterprise value$2.1M
Revenue$31.4M
Revenue per employee—
Profit margin46.54%
Debt to equity340.14

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$2.11
Dividend per share—
Revenue per share$4.65
Avg trading volume (30 day)$618K
Avg trading volume (10 day)$737K
Put-call ratio—

Macro factor sensitivity

Growth+1.7
Credit+4.9
Liquidity-1.9
Inflation-0.9
Commodities-2.5
Interest Rates-2.8

Valuation

Dividend yield0.00%
PEG Ratio-4.02
Price to sales0.43
P/E Ratio-4.02
Enterprise Value to Revenue0.07
Price to book0.48

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day—
Ex. dividend day—

News

Top 3 Health Care Stocks That May Rocket Higher In April

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga (April 28, 2025)
What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (January 31, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free